The Journal of Haemophilia Practice is an international, open-access, peer-reviewed journal that accepts papers from all members of the multidisciplinary bleeding disorders care team. Any manuscript that is relevant to current haemophilia practice will be considered for publication by our editorial review team. To this end, we positively welcome:
Reviews in any field of bleeding disorders that are of relevance to current clinical practice
Clinical Updates that describe current advances in any clinical field related to bleeding disorders
Editorials that address a particular topic of current interest.
All manuscripts submitted to The Journal of Haemophilia Practice will first be subject to a technical review, including a quality check of all the files submitted, including tables, figures and references. This will include a plagiarism check (see below). Manuscripts will then be reviewed by the Editor-in-Chief, who will decide whether or not to proceed to peer-review by members of our editorial board and invited experts. The identity of the reviewers will not be disclosed to the authors. The review procedure will result in one of three decisions:
Accept subject to revision
The editorial decision will be communicated to the authors as soon as the review process has been finalized. In case of revisions, the revised article will be sent to the reviewers who will decide on a new recommendation for revision, acceptance or rejection.
The estimated time from the submission to first decision is approximately 4-6 weeks, and from the final revision to acceptance is approximately 2 weeks. Prior to publication, the corresponding author will receive a proof of their article in order to confirm the accuracy of the text or suggest modifications.
CrossCheck Plagiarism Screening System
The editorial board is participating in a growing community of CrossCheck System's users in order to ensure that the content published is original and trustworthy. CrossCheck is a medium that allows for comprehensive manuscripts screening, aimed to eliminate plagiarism and provide a high standard and quality peer-review process.
All manuscripts to The Journal of Haemophilia Practice should be submitted via the Managing Editor: email@example.com.
Each submission should include a covering letter, signed on behalf of all co-authors by the corresponding author, stating that the manuscript is original and has not been published elsewhere or is currently under consideration by another journal (however, we accept that the manuscript may have been submitted to another journal previously). The corresponding author should state clearly whether or not there are any conflicts of interest.
Each submission should also include an Open Access License agreement. This can be downloaded via the Supplementary Materials section of the journal homepage and should be completed by the corresponding author. An Open Access Statement will be added to each manuscript accepted for publication.
Authorship should be based on the following four criteria:
Substantial contributions to the conception or design of the work AND
Drafting the work or revising it critically for important intellectual content AND
Final approval of the version to be published; AND
Agreement to be accountable for all aspects of the work in its entirety.
The corresponding author takes primary responsibility for communication with the journal during the manuscript submission, peer review, and publication process, and typically ensures that all the journal’s administrative requirements, such as providing details of authorship, ethics committee approval, clinical trial registration documentation, and gathering conflict of interest forms and statements, are properly completed, although these duties may be delegated to one or more co-authors.
Authors should not submit the same manuscript simultaneously to more than one journal, in the same or different language.
All articles should be submitted with a short abstract. For original articles, the abstract should be structured using the following headings: Background, Aims, Materials and Methods, Results and Conclusions. Submissions should also include 3-6 keywords for indexing. We do not specify word counts for articles, but as a guide, shorter items (such as case reports and small cohort studies) would usually range from 1000 to 3000 words. Reviews, larger, studies and qualitative studies, which require explanation of methodologies, may range from 3000 to 7,500 words.
Generic drug names should be used in text, tables, and figures.
Suppliers of drugs, equipment, and other brand-name material should be credited in parentheses (company, brand name, city, state, country).
The title of journals should be abbreviated according to the style of Index Medicus and spelled out in full if not listed in Index Medicus.
Examples of different reference styles are as follows:
• Reference to an article
Khair K, Holland M, Vidler V, Loran C, Harrington C. Why don't haemophilia nurses do research? Haemophilia 2012; 18: 540-3.
• Reference to a book
Jones P. Living with Haemophilia. 2002. Oxford: Oxford University Press.
• Reference to chapter in a book
Escobar MA, Roberts HR. Less common congenital disorders of hemostasis. In: Kitchens CS ed. Consultative Hemostasis and Thrombosis, 3rd edn. Philadelphia, PA: W.B. Saunders Company; 2013: in press.
• Reference to a webpage
European Medicines Agency (EMA). European Public Assessment Report (EPAR) NovoSeven Summary for the Public. 2009. Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/00007 4/human_med_000936.jsp&mid=WC0b01ac058001d124 (accessed 9 September 2013).
People who are reported in studies have a right to privacy that should not be violated without informed consent. Identifying information, including names, initials, dates of birth or hospital numbers, should not be published in written descriptions, photographs or pedigrees unless the information is essential for scientific purposes and the person (or parent or guardian) gives written informed consent for publication.
Informed consent for this purpose requires that an identifiable person be shown the manuscript to be submitted for publication. Authors should disclose to these participants whether any potential identifiable material might be available via the internet or in print after publication.
Each implicated individual’s consent should be written and archived with the authors. If the patient is a minor or lacks capacity to consent, the written informed consent of a parent or guardian must be given. If the person in the case study is deceased, written consent must be
sought from a relative. Without consent, a case report may be considered for publication if the patient is sufficiently anonymised according to ICMJE guidelines. Nonessential identifying details should always be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity.
Consent must be mentioned in the manuscript. We reserve the right to request copies of consent documentation. The Editor will make the final determination of what constitutes personally identifiable information on a case-by-case basis.
Editor-in-Chief Dr Kate Khair, Great Ormond Street Hospital, London, UK
Managing Editor Mike Holland, Haemnet, UK
Editorial Advisory Board Tami Barazani-Brutman, Sheba Medical Center at Sheba, Tel Hashomer Hospital, Israel Paul Batty, Queen Mary University of London, UK, and Queen’s University, Ontario, Canada Greig Blamey, Health Sciences Center, University of Alberta, Canada Erica Crilly, British Columbia Children's Hospital, Vancouver, Canada Janine Furmedge, The Royal Children’s Hospital Haemophilia Centre, Melbourne, Australia Rich Gorman, University of Exeter, UK Chris Guelcher, Children’s National Hospital, Washington, USA Chris Harrington, Royal Free Hospital, London, UK Cathy Harrison, Sheffield Haemophilia & Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK Dan Hart, The Royal London Hospital and Barts Health NHS Trust, London, UK Adam Jones, University of Sunderland, UK Radek Kaczmarek, Indiana University School of Medicine, USA Sebastien Lobet, Cliniques Universitaires Saint-Luc, Brussels, Belgium Paul McLaughlin, Royal Free Hospital, London, UK Greta Mulders, Erasmus University Medical Center, Rotterdam, The Netherlands James Munn, University of Michigan Hemophilia and Coagulation Disorders Program, Michigan, USA Declan Noone, European Haemophilia Association, Brussels Jamie O'Hara, University of Chester, Cheshire, UK Debra Pollard, Royal Free Hospital, London, UK BJ Ramsay, Wellington Haemophilia Centre, Wellington, New Zealand Dakota J. Rosenfelt, PharmD, Missouri, US Sylvia von Mackensen, Institute of Medical Psychology at the University Medical Centre, Hamburg, Germany Linda Myrin Westesson, Sahlgrenska University Hospital, Gothenburg, Sweden Michelle Witkop, National Hemophilia Foundation, USA
Technical Editor Kathryn Jenner, Haemnet, UK
Publisher De Gruyter Poland Bogumiła Zuga 32A Str. 01-811 Warsaw, Poland T: +48 22 701 50 15